BioCentury | Jul 10, 2020
Product Development

Evive meets in Phase III for chemotherapy-induced neutropenia; plus regulatory updates for Biogen, Eisai, Merck, AZ

...PARP - Poly(ADP-ribose) polymerase PD-1 (PDCD1) (CD279) - Programmed cell death 1 Sandi Wong, Assistant Editor Benegrastim (F-627) aducanumab...
BioCentury | Feb 2, 2018
Clinical News

Generon's benegrastim meets in Phase III for CIN

...myelotoxic chemotherapy with docetaxel and doxorubicin showing that a 20 mg dose of subcutaneous benegrastim (F-627...
...about 400 patients and is evaluating benegrastim compared with Neulasta pegfilgrastim from Amgen Inc. (NASDAQ:AMGN). Benegrastim...
...protein containing human G-CSF and human IgG2-Fc. Generon (Shanghai) Corp. Ltd., Shanghai, China Product: Benegrastim (F-627...
BioCentury | May 14, 2012
Clinical News

F-627: Phase II started

...Generon began an open-label, international Phase II trial to compare F-627 vs. Neulasta pegfilgrastim in about...
...Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.) markets Neulasta. Generon (Shanghai) Corp. Ltd. , Shanghai, China Product: F-627...
Items per page:
1 - 3 of 3